Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Aurinia Pharmaceuticals Inc. (AUPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.66 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 429.00K shares, a 71.68% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 1.23M shares, a 302.30% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 41.00K shares, a 90.26% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 408.00K shares, a 28.30% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 2.27M shares, a 6.51% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 2.43M shares, a 25.36% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.94M shares, a 25.97% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 2.62M shares, a 158.40% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 429.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.66M shares 10-Q · filed 2026-08-06 | 1.70M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.10M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.23M shares 10-Q · filed 2026-05-07 | 1.27M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.68M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.19M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 41.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 449.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.96M shares derived: sum of 3 quarters · filed 2026-02-26 | 2.27M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 408.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 1.92M shares derived: sum of 2 quarters · filed 2025-11-04 | 2.23M shares 10-Q · filed 2025-11-04 | 2.65M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 1.51M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 1.82M shares 10-Q · filed 2025-07-31 | 2.24M shares derived: sum of 3 quarters · filed 2025-07-31 | 2.56M shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 305.00K shares 10-Q · filed 2025-05-12 | 726.00K shares derived: sum of 2 quarters · filed 2025-05-12 | 1.04M shares derived: sum of 3 quarters · filed 2025-05-12 | 2.20M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 421.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 739.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 1.90M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.43M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 318.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.47M shares derived: sum of 2 quarters · filed 2024-11-07 | 2.01M shares 10-Q · filed 2024-11-07 | 2.93M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 1.16M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 1.69M shares 10-Q · filed 2024-08-01 | 2.61M shares derived: sum of 3 quarters · filed 2024-08-01 | 2.88M shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 532.00K shares 10-Q · filed 2024-05-02 | 1.46M shares derived: sum of 2 quarters · filed 2024-05-02 | 1.73M shares derived: sum of 3 quarters · filed 2024-05-02 | 1.94M shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 924.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 1.20M shares derived: sum of 2 quarters · filed 2024-02-15 | 1.41M shares derived: sum of 3 quarters · filed 2024-02-15 | 1.94M shares 10-K · filed 2024-02-15 |
| 2023-09-30 | 273.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 482.00K shares derived: sum of 2 quarters · filed 2023-11-02 | 1.01M shares 10-Q · filed 2023-11-02 | 2.12M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 209.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 739.00K shares 10-Q · filed 2023-08-03 | 1.85M shares derived: sum of 3 quarters · filed 2023-08-03 | 2.65M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 530.00K shares 10-Q · filed 2023-05-04 | 1.64M shares derived: sum of 2 quarters · filed 2023-05-04 | 2.44M shares derived: sum of 3 quarters · filed 2023-05-04 | 2.97M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 1.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 1.91M shares derived: sum of 2 quarters · filed 2023-02-28 | 2.44M shares derived: sum of 3 quarters · filed 2023-02-28 | 2.62M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 804.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 1.34M shares derived: sum of 2 quarters · filed 2022-11-03 | 1.51M shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 532.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 703.00K shares 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | 171.00K shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 1.01M shares 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 236.00K shares 10-K · filed 2022-02-28 | |||
| 2019-12-31 | 311.00K shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |